These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
308 related articles for article (PubMed ID: 1903069)
1. Hypercholesterolaemia: simvastatin and pravastatin alter cholesterol metabolism by different mechanisms. Owens D; Collins P; Johnson A; Tighe O; Robinson K; Tomkin GH Biochim Biophys Acta; 1991 Apr; 1082(3):303-9. PubMed ID: 1903069 [TBL] [Abstract][Full Text] [Related]
2. Tissue-selective acute effects of inhibitors of 3-hydroxy-3-methylglutaryl coenzyme A reductase on cholesterol biosynthesis in lens. Mosley ST; Kalinowski SS; Schafer BL; Tanaka RD J Lipid Res; 1989 Sep; 30(9):1411-20. PubMed ID: 2513368 [TBL] [Abstract][Full Text] [Related]
3. Improvement in the regulation of cellular cholesterologenesis in diabetes: the effect of reduction in serum cholesterol by simvastatin. Owens D; Stinson J; Collins P; Johnson A; Tomkin GH Diabet Med; 1991; 8(2):151-6. PubMed ID: 1827401 [TBL] [Abstract][Full Text] [Related]
4. Pharmacodynamics and pharmacokinetics of the HMG-CoA reductase inhibitors. Similarities and differences. Lennernäs H; Fager G Clin Pharmacokinet; 1997 May; 32(5):403-25. PubMed ID: 9160173 [TBL] [Abstract][Full Text] [Related]
5. Plasma mevalonic acid, an index of cholesterol synthesis in vivo, and responsiveness to HMG-CoA reductase inhibitors in familial hypercholesterolaemia. Naoumova RP; Marais AD; Mountney J; Firth JC; Rendell NB; Taylor GW; Thompson GR Atherosclerosis; 1996 Jan; 119(2):203-13. PubMed ID: 8808497 [TBL] [Abstract][Full Text] [Related]
6. Influence of pravastatin, a specific inhibitor of HMG-CoA reductase, on hepatic metabolism of cholesterol. Reihnér E; Rudling M; Ståhlberg D; Berglund L; Ewerth S; Björkhem I; Einarsson K; Angelin B N Engl J Med; 1990 Jul; 323(4):224-8. PubMed ID: 2114543 [TBL] [Abstract][Full Text] [Related]
7. Tissue-selective inhibition of cholesterol synthesis in vivo by pravastatin sodium, a 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor. Koga T; Shimada Y; Kuroda M; Tsujita Y; Hasegawa K; Yamazaki M Biochim Biophys Acta; 1990 Jul; 1045(2):115-20. PubMed ID: 2116173 [TBL] [Abstract][Full Text] [Related]
8. Treating hypercholesterolaemia with HMG CoA reductase inhibitors: a direct comparison of simvastatin and pravastatin. Lintott CJ; Scott RS; Sutherland WH; Bremer J Aust N Z J Med; 1993 Aug; 23(4):381-6. PubMed ID: 8240151 [TBL] [Abstract][Full Text] [Related]
9. HMG CoA reductase inhibitors as lipid-lowering agents: five years experience with lovastatin and an appraisal of simvastatin and pravastatin. Maher VM; Thompson GR Q J Med; 1990 Feb; 74(274):165-75. PubMed ID: 2111917 [TBL] [Abstract][Full Text] [Related]
10. Low-density lipoprotein cholesterol (LDL-C) levels and LDL-C goal attainment among elderly patients treated with rosuvastatin compared with other statins in routine clinical practice. Harley CR; Gandhi S; Blasetto J; Heien H; Sasane R; Nelson SP Am J Geriatr Pharmacother; 2007 Sep; 5(3):185-94. PubMed ID: 17996658 [TBL] [Abstract][Full Text] [Related]
11. In vitro myotoxicity of the 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors, pravastatin, lovastatin, and simvastatin, using neonatal rat skeletal myocytes. Masters BA; Palmoski MJ; Flint OP; Gregg RE; Wang-Iverson D; Durham SK Toxicol Appl Pharmacol; 1995 Mar; 131(1):163-74. PubMed ID: 7878672 [TBL] [Abstract][Full Text] [Related]
12. New developments in lipid-lowering therapy: the role of inhibitors of hydroxymethylglutaryl-coenzyme A reductase. Tobert JA Circulation; 1987 Sep; 76(3):534-8. PubMed ID: 3113763 [TBL] [Abstract][Full Text] [Related]
13. Treatment of primary hypercholesterolaemia. Short-term efficacy and safety of increasing doses of simvastatin and pravastatin: a double-blind comparative study. Stalenhoef AF; Lansberg PJ; Kroon AA; Kortmann B; De Haan AF; Stuyt PM; Kastelein JJ J Intern Med; 1993 Jul; 234(1):77-82. PubMed ID: 8326293 [TBL] [Abstract][Full Text] [Related]
14. Pravastatin inhibited the cholesterol synthesis in human hepatoma cell line Hep G2 less than simvastatin and lovastatin, which is reflected in the upregulation of 3-hydroxy-3-methylglutaryl coenzyme A reductase and squalene synthase. Cohen LH; van Vliet A; Roodenburg L; Jansen LM; Griffioen M Biochem Pharmacol; 1993 Jun; 45(11):2203-8. PubMed ID: 8517861 [TBL] [Abstract][Full Text] [Related]
15. Pharmacology and mechanism of action of the new HMG-CoA reductase inhibitors. Sirtori CR Pharmacol Res; 1990; 22(5):555-63. PubMed ID: 2126139 [TBL] [Abstract][Full Text] [Related]
17. Cost-effectiveness analysis of cholesterol-lowering therapies in Spain. Plans-Rubió P Am J Cardiovasc Drugs; 2006; 6(3):177-88. PubMed ID: 16780391 [TBL] [Abstract][Full Text] [Related]
18. HMG CoA reductase inhibitors in the treatment of hypercholesterolaemias. Aronson JK; Ng LL Q J Med; 1990 Feb; 74(274):111-5. PubMed ID: 2111916 [No Abstract] [Full Text] [Related]
19. [Comparison of 2 cholesterol synthesis inhibitors (simvastatin and pravastatin)]. Golay A; Lehmann T; James R; Pometta D Schweiz Med Wochenschr; 1993 Aug; 123(33):1553-8. PubMed ID: 8372340 [TBL] [Abstract][Full Text] [Related]
20. Comparative evaluation of the safety and efficacy of HMG-CoA reductase inhibitor monotherapy in the treatment of primary hypercholesterolemia. Hsu I; Spinler SA; Johnson NE Ann Pharmacother; 1995; 29(7-8):743-59. PubMed ID: 8520093 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]